Strong Clinical Trial Offering is Contributing to Growth in the Indian Pharmaceutical Market: companiesandmarkets.com

LONDON--(BUSINESS WIRE)-- The Indian pharmaceutical market increased in value to $22.6 billion in 2009, compared with $1.9 billion in 1980, according to a new report available on companiesandmarkets.com. The last few decades have seen an increasing amount of investment in the Indian pharmaceutical sector, with many large pharmaceutical companies taking advantage of the country’s low labour rates and skilled workforce.

Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force

http://www.companiesandmarkets.com/Market-Report/emerging-pharmaceutical-market-in-india-strategic-partnerships-between-domestic-and-international-pharmaceutical-players-are-the-driving-force-686524.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The pharmaceutical market in India is growing rapidly, and more and more high profile pharmaceutical companies are shifting R&D operations to the region, provoking analysts to forecast a 12-13% growth between 2011-2015.

Pharmaceutical companies are increasingly drawn to the Indian market on account of the country’s highly trained staff and low infrastructure and employment costs. In recent years the laws governing patents have also become more stringent, and coupled with the government’s generous tax incentive scheme for overseas R&D investment, the Indian pharmaceutical market is in a strong position to attract overseas investors.

Consolidation is likely to shape the future of the Indian pharmaceutical industry, with multiple mergers, acquisitions and deals expected over the next few years. The generic drugs sector will command a large share of the market as a large number of drugs fall off-patent in the coming years.

The market for clinical trials in India is burgeoning, as global pharmaceutical companies seek to minimise the high costs associated with drug development. Indian CRO facilities are well equipped and staffed with highly trained operatives, and in 2010, India conducted more clinical trials than Brazil, Russia or China.

The 108 page research piece, published in August 2011, thoroughly examines the Indian market for pharmaceuticals, biotechnology and outsourcing, with historical and forecast statistical data on a variety of market factors.

A SWOT analysis of some of India’s key foreign players is included e.g. Sanofi-Aventis, F. Hoffmann-La Roche Ltd., AstraZeneca, GlaxoSmithKline Pharmaceuticals Ltd and Abbott Laboratories.

Report Details:

http://www.companiesandmarkets.com/Market-Report/north-america-investment-decisions-in-communications-and-collaboration-products-and-services-556315.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe  Asia Pacific  India

INDUSTRY KEYWORDS:   Health  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.